Takeda Ventures and Astellas Venture Management both backed cell therapy developer Catamaran as it emerged from stealth.
US-based cancer treatment developer Catamaran Bio launched yesterday with $42m of series A funding from investors including Takeda Ventures and Astellas Venture Management, subsidiaries of pharmaceutical firms Takeda and Astellas.
The round was co-led by venture capital firms Sofinnova Partners and Lightstone Ventures and was also backed by healthcare fund manager SV Health Investors, the company’s founding investor.
Founded in September 2019, Catamaran is developing cell therapies for a broad range of cancers, including solid tumours. It aims to deliver…
